successfully engrafted donor marrow and who had positive CMV antigenemia. They received pre-emptive ganciclovir and showed complete recovery of marrow function thereWe performed pre-emptive ganciclovir therapy on two allogeneic bone marrow transplant (BMT) recipients after. with myelosuppression associated with cytomegalovirus (CMV) antigenemia after successful engraftment. During the hypoplastic phase, the nucleated cells in the bone Case report marrow and peripheral blood were revealed to be of donor origin by DNA fingerprinting. These two patients had CMV antigen in their peripheral leukocytes. FolPatient 1 lowing the pre-emptive ganciclovir treatment, both of them showed gradual recovery of granulocytes and A 17-year-old man with ALL(L 1 ) received BMT from his HLA-identical younger sister. The conditioning regimen platelets. They are still alive with stable bone marrow function. From these results, we suppose that infection consisted of total body irradiation 13.2 Gy on day −6 to −3 followed by cyclophosphamide at 50 mg/kg given on days or reactivation of CMV can suppress bone marrow function after bone marrow transplantation, and the −2 to −1. On 12 May 1995, bone marrow was infused. The number of infused mononuclear cells was 1.2 × 10 8 /kg. pre-emptive ganciclovir therapy based on the CMV antigenemia may be beneficial if bone marrow function Trimethoprim-sulfamethoxazole for prophylaxis of Pneumocystis carinii prior to BMT, and acyclovir for prophydeteriorates after engraftment. Keywords: BMT; CMV antigenemia; ganciclovir; prelaxis of herpes simplex virus were given. Cyclosporin and methotrexate for prevention of acute graft-versus-host disemptive therapy ease (GVHD) were prescribed. On day 14 post-BMT, restriction fragment length polymorphism (RFLP) was done and it revealed perfect engraftment with donor cells CMV infection is frequently associated with graft failure (Figure 1) . A bone marrow biosy on day +21 showed 30% in bone marrow transplant recipients. The mechanism of cellularity which indicated successful engraftment. On day CMV-induced myelosuppression is unknown but it could 33 post-BMT, the CMV antigenemia assay by CMV-vue be related to a direct toxic effect on marrow progenitors or kit (Incstar, Stillwater, MA, USA) was negative. At that an alteration of the marrow microenvironment.
bone marrow was infused. The number of infused mononuclear cells was 1.1 × 10 8 /kg. Prophylaxis of infection and prevention of acute GVHD were identical with patient 1. A bone marrow biosy on day +21 showed 40% cellularity with trilineage precursor cells, and RFLP showed perfect engraftment (Figure 3 ). At that time, peripheral blood counts were hemoglobin 10.3 g/dl, hematocrit 30.9%, WBC 3.2 × 10 9 /l with differential counts of segemented neutrophils 50%, lymphocytes 30%, monocytes 20%, and platelets 54 × 10 9 /l. Following engraftment, she developed acute skin GVHD (I/II). Steroid pulse therapy was given and the skin lesion improved. On day 56 post-BMT, CMV antigenemia revealed 17 antigen postive cells in 50 000 peripheral leukocytes. Pre-emptive ganciclovir therapy was started. After 2 weeks of ganciclovir treatment, CMV antigenemia converted to negative and the peripheral blood cell counts recovered ( Figure 4) . As of December 1995, she has stable bone marrow functions without any problem. Graft failure is an important complication following allogeneic BMT. Various factors such as rejection, GVHD, drugs and infectons have been implicated in the development of the syndrome. 1-4 Among them, we exclude rejection by identifying donor origin cells using restriction fragment length polymorphism (RFLP) and found that these two patients had successfully engrafted with donor cells.
We used drugs to prevent infections and acute GVHD, and these drugs might be a cause of bone marrow suppression. Trimethoprim-sulfamethoxazol was prescribed only before transplantation because the incidence of Pneumocystis carinii infection is very rare in our country. Acyclovir was given orally and minimally (1000 mg/day). Consequently these two drugs were unlikely to be the cause of bone marrow suppression. Methotrexate was presecribed as per the Seattle protocol (day +1, +3, +6, +11; 10 mg/m 2 ), 
Patient 2
A 34-year-old woman received BMT for severe aplastic anemia (SAA). Her donor was her HLA and blood typematched elder brother. The conditioning regimen was plas-
mapheresis three times on day −10 to −8, ATG (anti-human carbazine 900 mg on days −6, −4, −2. On 16 March 1995, cells infected with CMV are insensitive to the stimulatory effect of granulocyte colony-stimulating factor (G-CSF), and granulocyte-macrophage colony-stimulating factor (GM-CSF).
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Our two patients were treated with ganciclovir (5 mg/kg, twice daily) just when the CMV antigenemia assay became positive. Ganciclovir remains the most effective antiviral agent, especially in its protective and therapeutic potency for CMV 7, [12] [13] [14] However, it has some adverse effect such as bone marrow suppression. We carefully monitored the peripheral blood counts of these patients and performed serial CMV antigenemia assays at 1-week intervals. Fortunately, there was an improvement of peripheral blood cells in these patients with negative conversion of CMV antigenemia. In our opinion, the myelosuppression in these patients was strongly associated with CMV antigenemia and ganciclovir might have reduced the burden of CMV and thereafter abolished its myelosuppressive action.
In conclusion, these two cases suggest that the preemptive ganciclovir therapy of BMT recipients with positive CMV antigenemia could salvage suppressed marrow function in spite of the myelotoxic effect of granciclovir. tation. [1] [2] [3] 8, 9 In the CMV antigenemia assay using CMV-vue 107-111. kit, positive CMV antigenemia was found in both patients. than prophylactic ganciclovir therapy. 965-1973. The mechanism of CMV-induced myelosuppression may 
